Bayer’s flupyradifurone approved by EC
Bayer CropScience has reached an important milestone towards the market introduction of its innovative insecticide Sivanto prime in Europe.
Pharmaceuticals, Biotechnology and Life Sciences
Bayer CropScience has reached an important milestone towards the market introduction of its innovative insecticide Sivanto prime in Europe.
Eli Lilly and Company has revealed plans to expand its global research and development (R&D) headquarters in Indianapolis, Indiana.
A single variation in the gene for brain-derived neurotropic factor (BDNF) may influence obesity in children and adults, according to a new study funded by the National Institutes of Health.
Eylea is now also approved for the treatment of visual impairment due to myopic choroidal neovascularization (myopic CNV).
United States Food and Drug Administration (FDA) has approved Lonsurf (trifluridine and tipiracil) tablets for the treatment of patients with metastatic colorectal cancer who have been previously…
Allergan plc has confirmed that it has been approached by Pfizer Inc. and is in preliminary friendly discussions regarding a potential business combination transaction.
The Novartis Foundation and its partners have begun screening patients in the Community-based Hypertension Improvement Project (ComHIP), a two-year program designed to evaluate the impact of an innovative healthcare model on hypertension management and control in Ghana
U.S. Food and Drug Administration (FDA) has approved BMS’s Yervoy (ipilimumab) 10 mg/kg for the adjuvant treatment of patients with cutaneous melanoma with pathologic involvement of regional lymph nodes of more than 1 mm who have undergone complete resection including total lymphadenectomy.
Plandaí Biotechnology, Inc., has executed an Exclusive Distribution Agreement with Bal Pharma Ltd., an India-based manufacturer and exporter of pharmaceutical finished formulation/bulk drugs and distributor of nutraceuticals ingredients.
Oxford BioMedica plc, a gene and cell therapy group, has announced that GlaxoSmithKline PLC (GSK) has exercised an option to obtain a non-exclusive licence for two rare orphan disease indications under Oxford BioMedica’s LentiVector platform technology patents.